Montelukast Teva

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis by reducing inflammation and bronchoconstriction in patients who require long‑term control.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory and allergic conditions.

- Asthma: reduces the frequency of asthma exacerbations and improves lung function in persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after vigorous physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Abdominal pain: discomfort or cramping in the stomach region. - Cough: transient irritation of the airway. - Dyspepsia: indigestion or feeling of fullness. - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Fatigue: occasional tiredness or lack of energy.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Angioedema: rapid swelling of the face, lips, tongue or throat. - Hepatic injury: abnormal liver function tests or jaundice. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Anaphylaxis: rare systemic allergic reaction. - Blood dyscrasias: uncommon blood cell abnormalities.

Before initiating therapy, consider the following safety points.

- Monitor liver function: periodic testing is advised for patients with pre‑existing hepatic disease. - Psychiatric history: use with caution in individuals with depression or suicidal ideation. - Acute asthma attacks: not a rescue medication; patients should retain a fast‑acting bronchodilator. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Drug interactions: review concomitant medications for potential CYP450 effects. - Store below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, reducing montelukast exposure. - Rifampin: strong CYP3A4 inducer that may lower therapeutic levels. - Ketoconazole: potent CYP3A4 inhibitor, potentially increasing montelukast concentrations.

Moderate Interactions (Monitor Closely): - Zafirlukast or other leukotriene modifiers: additive risk of neuropsychiatric effects. - Warfarin: possible alteration of anticoagulant effect, monitor INR. - Oral contraceptives: may experience reduced efficacy; advise additional contraceptive measures.